If the sFlt-1:PlGF ratio is used for patients who were hospitalized admitted between 23 and 35 weeks of gestation with hypertensive disorders, the test is a complementary risk stratification screen to add to the diagnostic work-up of PE-SF. This evidence concerns the gene PGF and hypertensive disorder.